Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). uri icon

authors

  • Ball, Brian J
  • Sandhu, Karamjeet
  • Otoukesh, Salman
  • Amanam, Idoroenyi
  • Pourhassan, Hoda
  • Andrew Artz, MD, MS
  • Curtin, Peter
  • Stein, Anthony
  • Nakamura, Ryotaro
  • Marcucci, Guido
  • Smith, Eileen
  • Arslan, Shukaib
  • Pullarkat, Vinod
  • Aldoss, Ibrahim
  • Koller, Paul
  • Ngo, Dat
  • Afkhami, Michelle
  • Salhotra, Amandeep
  • Al-Malki, Monzr
  • Aribi, Ahmed
  • Ali, Haris

publication date

  • January 1, 2022